Investigating the role of FGF23 peptides in chronic kidney disease
Role of FGF23 peptides in chronic kidney disease (CKD)
This study is looking at how a hormone called FGF23, which comes from your bones, affects people with chronic kidney disease (CKD) and aims to find better ways to treat related health problems like heart issues and anemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10978217 on NIH RePORTER |
What this research studies
This research focuses on understanding how FGF23 peptides, which are hormones secreted by bone, affect patients with chronic kidney disease (CKD). It explores the relationship between these peptides and various health issues such as cardiovascular mortality, anemia, and iron metabolism disturbances. By examining the secretion and physiological functions of different forms of FGF23, the study aims to identify new therapeutic approaches to mitigate the adverse outcomes associated with CKD. Patients may benefit from insights that could lead to improved treatments targeting FGF23-related complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic kidney disease, particularly those experiencing complications like anemia or cardiovascular issues.
Not a fit: Patients with acute kidney injury or those not diagnosed with chronic kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve health outcomes for patients with chronic kidney disease.
How similar studies have performed: While the role of FGF23 in CKD is being explored, this specific investigation into the distinct functions of FGF23 peptides is relatively novel and has not been extensively tested in prior research.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: David, Nicolae Valentin — Northwestern University at Chicago
- Study coordinator: David, Nicolae Valentin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.